Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1901. Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK

. The transition probabilities were not reported. Measure of benefits used in the economic analysis The outcomes were measured in life-years and quality-adjusted life-years (QALYs), and were derived from EQ-5D valuations of health states using both public and patient tariffs. They were discounted at a rate of 1.5%. Quality of life data relating to symptoms experienced by patients with Type 2 diabetes were used in the absence of data for those with Type 1 diabetes. Direct costs The direct costs to the health (...) Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK Shearer A, Bagust A, Sanderson D, Heller S, Roberts S Record Status This is a critical abstract of an economic

2004 NHS Economic Evaluation Database.

1902. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria

Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Smith D G, Nguyen A B, Peak C N (...) , Frech F H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared two treatment options for patients with Type 2 diabetes and microalbuminuria. The treatment options were the angiotensin II receptor blocker valsartan

2004 NHS Economic Evaluation Database.

1903. Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors Full Text available with Trip Pro

Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors Hayashino Y, Nagata-Kobayashi S, Morimoto T, Maeda K, Shimbo (...) : no screening; exercise electrocardiography followed by coronary angiography (CAG) if positive; exercise echocardiography followed by CAG if positive; and exercise single-photon emission computed tomography (SPECT) followed by CAG if positive. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population comprised cohorts of men aged between 50 and 70 with Type 2 diabetes mellitus and 10 possible pairs of atherogenic risk factors. Such risk factors

2004 NHS Economic Evaluation Database.

1904. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for Type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials

Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for Type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

1905. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with Type 2 diabetes: a projection using the CORE diabetes model Full Text available with Trip Pro

What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with Type 2 diabetes: a projection using the CORE diabetes model What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with Type 2 diabetes: a projection using the CORE diabetes model What impact would pancreatic beta-cell preservation have on life (...) expectancy, quality-adjusted life expectancy and costs of complications in patients with Type 2 diabetes: a projection using the CORE diabetes model Palmer A J, Roze S, Valentine W J, Minshall M E, Lammert M, Oglesby A, Hayes C, Spinas G A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability

2004 NHS Economic Evaluation Database.

1906. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada Full Text available with Trip Pro

Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada Caro J J, Getsios D, Caro I, Klittich W S, O'Brien J A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) . If this is not the case, or for patients who cannot or will not comply with a lifestyle programme, pharmacological prevention strategies are economically viable alternatives. Source of funding Supported in part by a grant from Bayer plc to Caro Research. Bibliographic details Caro J J, Getsios D, Caro I, Klittich W S, O'Brien J A. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. Diabetic Medicine 2004; 21(11): 1229-1236 PubMedID DOI Other publications of related interest

2004 NHS Economic Evaluation Database.

1907. Cost effectiveness of ACE inhibitor treatment for patients with Type 1 diabetes mellitus

Cost effectiveness of ACE inhibitor treatment for patients with Type 1 diabetes mellitus Cost effectiveness of ACE inhibitor treatment for patients with Type 1 diabetes mellitus Cost effectiveness of ACE inhibitor treatment for patients with Type 1 diabetes mellitus Dong F B, Sorensen S W, Manninen D L, Thompson T J, Narayan V, Orians C E, Gregg E W, Eastman R C, Dasbach E J, Herman W H, Newman J M, Narva A S, Ballard D J, Engelgau M M Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The initiation of treatment with an angiotensin-converting enzyme (ACE) inhibitor (captopril) was assessed in adult patients with Type I diabetes. Treatment immediately after diagnosis was compared with treatment after the onset

2004 NHS Economic Evaluation Database.

1908. Losartan reduces the costs associated with nephropathy and end-stage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective

Losartan reduces the costs associated with nephropathy and end-stage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective Losartan reduces the costs associated with nephropathy and end-stage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective Losartan reduces the costs associated with nephropathy and end-stage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from (...) therapies (e.g. calcium-channel antagonists, diuretics, alpha-blockers, beta-blockers, and centrally acting agents) for the treatment of Type 2 diabetes patients with nephropathy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with nephropathy from Type II diabetes. Setting The setting was secondary care. The economic study was conducted in Canada. Dates to which data relate The effectiveness evidence and most

2004 NHS Economic Evaluation Database.

1909. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. (Abstract)

The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. The incidence of childhood type 1 diabetes has risen over the past 50 years. We compared the frequency of HLA class II haplotypes in 194 patients diagnosed more than 50 years ago and 582 age-matched and sex-matched individuals diagnosed between 1985 and 2002. The proportion of high-risk susceptibility genotypes was increased in the earlier cohort (p=0.003), especially in those diagnosed (...) at age 5 years or younger, which is consistent with the hypothesis that the rise of type 1 diabetes is due to a major environmental effect.

2004 Lancet

1910. Association of intercellular adhesion molecule-1 gene with type 1 diabetes. (Abstract)

Association of intercellular adhesion molecule-1 gene with type 1 diabetes. Intercellular adhesion molecule-1 (ICAM-1) functions via its ligands, the leucocyte integrins, in adhesion of immune cells to endothelial cells and in T cell activation. The third immunoglobulin-like extracellular domain binds integrin Mac-1 and contains a common non-conservative aminoacid polymorphism, G241R. Phenotypically, ICAM-1 has been associated with type 1 diabetes, a T-cell-mediated autoimmune disease. We (...) assessed two independent datasets, and noted that R241 was associated with lower risk of type 1 diabetes than is G241 (3695 families, relative risk 0.91, p=0.03; 446 families, 0.60, p=0.006). Our data indicate an aetiological role for ICAM-1 in type 1 diabetes, which needs to be confirmed in future genetic and functional experiments.

2003 Lancet

1911. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. (Abstract)

Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Type 2 diabetes mellitus is a metabolic disease of carbohydrate metabolism. However, it should also be considered a vascular disease because diabetic patients have a strong predilection for atherosclerosis. With the increasing prevalence and earlier age at onset of diabetes, the projected effect of diabetes on cardiovascular health and resource utilization is sobering. The mechanisms (...) of the high rate of atherosclerosis are multifactorial and give clinicians and researchers insights into potential preventive therapies. Effective pharmacologic and lifestyle interventions are available for primary and secondary prevention of cardiovascular complications. However, data show that these interventions continue to be underutilized. Treatment of patients with type 2 diabetes and coronary artery disease is similar to that of patients with coronary artery disease alone. However, patients

2003 Annals of Internal Medicine

1912. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. Full Text available with Trip Pro

Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. Dietary factors modifying type 1 diabetes mellitus (DM) risk have been proposed, but little is known if they trigger the islet autoimmunity that precedes clinical disease.To determine whether breastfeeding duration, food supplementation, or age at introduction of gluten-containing foods influences the risk of developing islet autoantibodies.Prospective natural history cohort study conducted from 1989 to 2003 (...) in inpatient/outpatient clinics in Germany.The BABYDIAB study follows newborn children of parents with type 1 DM. Eligibility requirements were met in 1610 children. Blood samples were obtained at birth, age 9 months, 2, 5, and 8 years. Dropout rate was 14.4% by age 5 years. Breastfeeding data were obtained by prospective questionnaires (91% complete), and food supplementation data were obtained by family interview (72% for food supplementation and 80% for age of gluten introduction).Development of islet

2003 JAMA

1913. National surveillance for type 2 diabetes mellitus in Taiwanese children. Full Text available with Trip Pro

National surveillance for type 2 diabetes mellitus in Taiwanese children. Despite a disturbing trend of increasing prevalence of type 2 diabetes mellitus (DM) in childhood, little is known about the epidemiology of childhood type 2 DM, especially in the Taiwanese population.To study the rate and risk factors for childhood type 2 DM based on a nationwide screening program in Taiwan.Screening in 1999 for type 2 DM using urine and blood testing and confirmed by follow-up telephone survey among (...) schoolchildren aged 6 to 18 years in Taiwan, followed by a nested case-control study conducted in 2002 comparing 137 children with type 2 DM with 1,000 randomly selected children without diabetes chosen to represent the age and sex distribution of the whole student population.Rate and identification of risk factors associated with childhood type 2 DM.The rate of newly identified diabetes was 9.0 per 100,000 for boys and 15.3 per 100,000 for girls. Follow-up at 3 years revealed that, of 253 children

2003 JAMA

1914. What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. Full Text available with Trip Pro

What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. To evaluate systematically the review literature on type 2 diabetes to assess transmission of the findings of the United Kingdom prospective diabetes study (UKPDS), an important source of recent valid patient oriented evidence that matters (POEMs).Inception cohort analysis of the recent medical literature.Thirty five reviews on treatment of type 2 diabetes.Presentation of three types (...) ) of the reviews did not report that diabetic patients with hypertension benefit more from good blood pressure control than good blood glucose control. No review pointed out that treatment of overweight patients with type 2 diabetes with insulin or sulphonylurea drugs had no effect on microvascular or macrovascular outcomes. Thirteen reviews recommended drugs as first line treatment for which we do not have patient oriented outcomes data. The average validity assessment score was 1.3 out of a possible score

2003 BMJ

1915. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. Full Text available with Trip Pro

Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. Kidney disease in type 2 diabetes mellitus (DM) is more heterogeneous than in type 1 DM. Reduced glomerular filtration rate (GFR) among individuals with type 2 DM may not always be due to classic diabetic glomerulosclerosis, which is associated with albuminuria and retinopathy.To determine the prevalence of chronic renal insufficiency (CRI), defined as a GFR less than 60 mL/min per 1.73 (...) m2 body surface area (BSA) in the absence of microalbuminuria or macroalbuminuria and diabetic retinopathy among adults with type 2 DM.Cross-sectional analysis of adults aged 40 years or older with type 2 DM in the Third National Health and Nutrition Examination Survey, a probability sample of the total civilian US noninstitutionalized population conducted from 1988-1994.The GFR per 1.73 m2 BSA, calculated with serum creatinine, urea nitrogen, and serum albumin levels using the Modification

2003 JAMA

1916. Regression of microalbuminuria in type 1 diabetes. (Abstract)

Regression of microalbuminuria in type 1 diabetes. In the present study, we aimed to determine the frequency of a significant reduction in urinary albumin excretion and factors affecting such reduction in patients with type 1 diabetes and microalbuminuria.The study included 386 patients with persistent microalbuminuria, indicated by repeated measurements of urinary albumin excretion (estimated on the basis of albumin-to-creatinine ratios) in the range of 30 to 299 microg per minute during (...) had a hazard ratio for regression of 3.0 (95 percent confidence interval, 1.5 to 6.0), as compared with patients with no salutary levels of any modifiable factor.Frequent regression of microalbuminuria in patients with type 1 diabetes indicates that elevated urinary albumin excretion does not imply inexorably progressive nephropathy. Identification of the multiple determinants of the regression of microalbuminuria has implications for current theories about the mechanisms of early diabetic

2003 NEJM

1917. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. (Abstract)

Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Type 2 diabetes is affected by genetics and environmental factors. We aimed to assess the effect of an in-utero diabetic environment independently of the genetic background for type 2 diabetes.We measured insulin sensitivity and insulin secretion in response to oral and intravenous glucose in 15 non-diabetic adult offspring of mothers with type 1 diabetes (exposed participants) and 16 offspring of type 1 diabetic (...) glucose ingestion was 1007 (429) in people with impaired glucose tolerance, 2829 (1701) in those with normal glucose tolerance, and 3224 (1352) in controls (p=0.04).Exposure to a diabetic environment in utero is associated with increased occurrence of impaired glucose tolerance and a defective insulin secretory response in adult offspring, independent of genetic predisposition to type 2 diabetes. This insulin secretory defect could be related to low parasympathetic tone. Epidemiological studies

2003 Lancet

1918. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. (Abstract)

Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. Newer insulin therapies, including the concept of physiologic basal-prandial insulin and the availability of insulin analogues, are changing clinical diabetes care. The key to effective insulin therapy is an understanding of principles that, when implemented, can result in improved diabetes control.To systematically review the literature regarding insulin use in patients with type 1 and type 2 diabetes (...) mellitus (DM).A MEDLINE search was performed to identify all English-language articles of randomized controlled trials involving insulin use in adults with type 1 or type 2 DM from January 1, 1980, to January 8, 2003. Bibliographies and experts were used to identify additional studies.Studies were included (199 for type 1 DM and 144 for type 2 DM, and 38 from other sources) if they involved human insulins or insulin analogues, were at least 4 weeks long with at least 10 patients in each group

2003 JAMA

1919. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. Full Text available with Trip Pro

Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. Current public health campaigns to reduce obesity and type 2 diabetes have largely focused on increasing exercise, but have paid little attention to the reduction of sedentary behaviors.To examine the relationship between various sedentary behaviors, especially prolonged television (TV) watching, and risk of obesity and type 2 diabetes in women.Prospective cohort study (...) conducted from 1992 to 1998 among women from 11 states in the Nurses' Health Study. The obesity analysis included 50 277 women who had a body mass index (BMI) of less than 30 and were free from diagnosed cardiovascular disease, diabetes, or cancer and completed questions on physical activity and sedentary behaviors at baseline. The diabetes analysis included 68 497 women who at baseline were free from diagnosed diabetes mellitus, cardiovascular disease, or cancer.Onset of obesity and type 2 diabetes

2003 JAMA

1920. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. (Abstract)

Screening for type 2 diabetes mellitus in adults: recommendations and rationale. This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for type 2 diabetes in adults and updates the 1996 recommendations on this topic. The complete USPSTF recommendation and rationale statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site ( http://www.preventiveservices.ahrq.gov

2003 Annals of Internal Medicine